Gilead Sciences, a biotech company, experienced a notable increase in its stocks. Although the company primarily focuses on cancer and HIV treatments, some analysts have attempted to position it as an obesity drug developer. Analyst Michael Yee from Jefferies recently published a note suggesting that Gilead’s recent patents and prior data indicate the potential for an early-stage metabolic program that could eventually target obesity. The company will also be presenting data on monkeys at an upcoming conference related to diabetes.
